Galectin-3 as the marker of hypertrophy and myocardial dysfunction in males with essential hypertension, carriers of polymorphic genes of angiotensin ii type 1 receptor


  • V.O. Ruzhanskaya National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • V.G Sivak National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • O.O. Sakovych National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • V.M. Zhebel National Pirogov Memorial Medical University, Vinnytsya, Ukraine
Keywords: polymorphism of angiotensin II type 1 receptor gene (AT1R), galectin-3, brain natriuretic peptide, structural and functional changes in the myocardium, essential hypertension, chronic heart failure

Abstract

One of the main etiological causes of development of heart failure is essential hypertension. The diagnosis of heart failure is usually made on the basis of comprehensive analysis of medical history, sonographic and biochemical examination. Normal ejection fraction does not exclude dyspnea of cardiac origin. Objective: to determine the role of galectin-3 as a marker of structural and functional changes of the myocardium in males with essential hypertension and CHF, carriers of polymorphic AT1R genes, residents of Podillya region of Ukraine. In this contingent, the surveyed were studied сoncentrations of galectin-3 and brain natriuretic peptide (BNP), parameters of central and systemic hemodynamics in carriers of polymorphic variants of angiotensin II type 1 receptor gene (АТ1R) - individuals with no cardiovascular pathology (n=79), male patients with II-III degree essential hypertension (EH) and hypertrophy of the myocardium (n=62), and essential hypertension (n=50) complicated by chronic heart failure (CHF), residents of Podillya region of Ukraine, were studied. Genotyping of АТ1R gene was performed using polymerase chain reaction. Galectin-3 and brain natriuretic peptide levels were determined by enzyme immunoassay. Structural and functional parameters of myocardium were assessed by ultrasound using the apparatus “RADMIR ULTIMARA”. Statistical analysis of the results obtained was done on personal computer using standard statistical package Statistica 10.0. The data are represented as mean values (M) and standard deviations (±m). Carriers of C allele of angiotensin II type 1 receptor gene were found to be dominating among the males with essential hypertension and resultant myocardial hypertrophy. Concentrations of galectin-3 and brain natriuretic peptide were significantly higher in men with essential hypertension and essential hypertension associated with chronic heart failure, as compared to those with no cardiovascular diseases, as well as the carriers of C allele of angiotensin II type 1 receptor gene. It was found that concentrations of study biomarkers were higher in individuals with severe and eccentric left ventricular hypertrophy, as well as in those with decreased ejection fraction of the left ventricle. Therefore, those biomarkers can be used in complex diagnosis of left ventricular hypertrophy in essential hypertension and the development of chronic heart failure in such patients.

References

[1] Abuzaanona, A., & Lanfear, D. (2017). Pharmacogenomics of the Natriuretic Peptide System in Heart Failure. Curr. Heart Fail. Rep., 14, 536-542. doi.org/10.1007/s11897-017-0365-5.

[2] Amosova, E. M. (2001). The effect of early remodeling of the left ventricle on the state of its systolic and diastolic function in patients with acute myocardial infarction in the dynamics of the hospital period. Ukrainian Cardiology Magazine, 1, 17-20.

[3] Andreev, D. A., Mazarkina, I. A., Gitel, E. N., Dobrovolsky, A. V., Kukes, V. G., Sychev, D. A., & Khoreva, V. A. (2007). Changes in the brain natriuretic peptide in the treatment of decompensation of chronic heart failure. Creative cardiology, 1-2, 136-142.

[4] Beltrami, M., Ruocco, G., Dastidar, A. G., Franci, B., Lucani, B., Aloia, E. ... Palazzuoli, A. (2016). Additional value of galectin-3 to BNP in acute heart failure patients with preserved ejection fraction. Clinica Chimica Acta., 457, 99-105. doi: 10.1016/j.cca.2016.04.007.

[5] Berezin, A. E. (2013). Galectin-3 as a phenotypic indicator of cardiovascular risk in patients with heart failure. Zaporozhye Medical Journal, 6, 58-62.

[6] Bilovol, O. M., Shalimova, A. S., & Kochueva, M. M. (2014). Comorbidity of hypertonic disease and type 2 diabetes is an urgent problem of modern medicine. Ukrainian Therapeutic Journal, 1, 11-17.

[7] Blanar, O. L., & Zhebel, V. M. (2009). Polymorphism of the AT1R gene and vascular function of the endothelium in patients with chronic heart failure, which complicated the course of hypertension. Scientific herald of Uzhgorod University, 35, 39-43.

[8] Burkly, L. C., Michaelson, J. S., & Zheng, T. S. (2011). TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol. Rev., 244, 99-114. doi: 10.1111/j.1600-065X.2011.01054.x

[9] Chacon, M. R., Richart, C., Gomez, J. M., Lucani, B., Aloia, E., Nuti, R., & Palazzuoli, A. (2006). Expression of TWEAK and its receptor Fn14 in human subcutaneous adipose tissue. Relationship with other inflammatory cytokines in obesity. Cytokine., 33, 129-137. doi: 10.1016/j.cyto.2005.12.005.

[10] Chandra, S., Narang, R., Sreenivas, V., Bhatia, J., Saluja, D., & Srivastava, K. (2014). Association of angiotensin II type 1 receptor (A1166C) gene polymorphism and its increased expression in essential hypertension: a case-control study. PLoS One., 9(7):e101502. doi: 10.1371/journal.pone.0101502.

[11] de Boer, R. A., Voors, A. A., Muntendam, P., van Gilst, W. H., & van Veldhuisen, D. J. (2009). Galectin-3: a novel mediator of heart failure development and progression. Eur. J. Heart Fail., 11:811-817. doi: 10.1093/eurjhf/hfp097.

[12] Devi, N., Lakshmi, V., Padhy, K., Veerraju, P., & Mahapatra, S. (2012). Association of ACE, AGT and AT1R gene polymorphisms with severity of Coronary Artery Disease. IOSR Journal of dental and medical scients., 2, 11-18. doi: 10.9790/0853-0241118.

[13] Edelmann, F., Holzendorf, V., Wachter, R., Nolte, K., Schmidt, A. G., Kraigher-Krainer, E. … Pieske, B. M. (2015). Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure, 17, 214-223. doi: 10.1002/ejhf.203.

[14] Kikuya, M., Sugimoto, K., Katsuya, T., Suzuki, M., Sato, T., Funahashi, J. … Matsubara, M. (2003). A/C1166 gene polymorphism of the angiotensin II type 1 receptor (AT1) and ambulatory blood pressure: the Ohasama Study. Hypertens Res., 26:141-145.

[15] Kinoshenko, K. Yu., & Mischuk, N. E. (2017). Diastolic dysfunction of the left ventricle. Medications of Ukraine, 8, 50-56.

[16] Lala, R. I., Lungeanu, D., Darabantiu, D., Pilat, L., & Puschita, M. (2018). Galectin-3 as a marker for clinical prognosis and cardiac remodeling in acute heart failure. Herz., 43, 146-155. doi: 10.1007/s00059-017-4538-5.

[17] McCullough, P. A., Olobatoke, A., & Vanhecke, T. E. (2011). Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev. Cardiovasc. Med., 12, 200-210. doi: 10.3909/ricm0624.

[18] Nikonova, E. S., Suslova, T. E, Ryabov, V. V., & Shurupov, V. S. (2013). Brain natriuretic peptide in patients with chronic heart failure with a reduced and maintained ejection fraction. Clinical laboratory diagnostics, 8, 21-23.

[19] Niu, W., & Qi, Y. (2010). Association of the angiotensin II type 1 receptor gene +1166 A>C polymorphism with hypertension risk: evidence from a meta-analysis of 16474 subjects. Hypertens Res., 33, 1137-43. doi: 10.1038/hr.2010.156.

[20] Novoyatleva, T., Janssen, W., Wietelmann, A., Schermuly, R. T., & Engel, F. B. (2013). TWEAK/Fn14 axis is a positive regulator of cardiac hypertrophy. Cytokine, 64, 43-45. doi: 10.1016/j.cyto.2013.05.009.

[21] Pereira, A. R., & Falcao, L. M. (2015). Galectin-3, a prognostic marker – and a therapeutic target? Revista Portuguesa de Cardiologia, 34, 201-208. doi: 10.1016/j.repc.2014.10.005.

[22] Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G., Cleland, J. G. F., & Linde, C. (2016). 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 37, 2129-2200. doi:10.1002/ejhf.592.

[23] Poirier, O., Georges, J. L., & Ricard, S. (1998). New polymorphisms of the angiotensin II type 1 receptor gene and their associations with myocardial infarction and blood pressure: the ECTIM study. Etude Cas-Temoin de I’Infarctus du Myocarde. J. Hypertens., 10, 1443-1447.

[24] Sakovich, O. O., Zhebel, V. M., & Gumenyuk, A. F. (2011). Inheritance of polymorphic genotypes of the angiotensin II receptor type II type and risk factors for the development of hypertonic disease in women living in the Vinnytsia region. Zaporozhye Medical Journal, 4, 44-47.

[25] Starzhinska, O. L., & Zhebel, V. M. (2005). Features of the course of hypertension in men with different genotypes of the angiotensin II receptor type I. Biomedical and Biosocial Anthropology, 4, 171-177.

[26] Suarez, G., & Meyerrose, G. (2014). Heart failure and galectin 3. Annals of Translational Medicine, 2, 86-92. doi: 10.3978/j.issn.2305-5839.2014.09.10.

[27] Tsuleyko, V. J., Matviichuk, N. V., & Kinoshenko, K. Yu. (2014). Galectin-3 in patients with chronic heart failure. Ukrainian Cardiology Magazine, 3, 77-81.

[28] Yin Qiu-Sheng, Shi Bing, Dong Lan, & Bi Lei. (2014). Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure. J. Geriatr. Cardiol., 11, 79-82. doi: 10.3969/j.issn.1671-5411.2014.01.014.

[29] Zhang, T., Shao, B., & Liu, G-A. (2017). Research on clinical value of galectin-3 in evaluating the prognosis of acute heart failure. Europian review for medical and pharmacological sciences, 21, 4406-4410.
Published
2018-12-27
How to Cite
Ruzhanskaya, V., Sivak, V., Sakovych, O., & Zhebel, V. (2018). Galectin-3 as the marker of hypertrophy and myocardial dysfunction in males with essential hypertension, carriers of polymorphic genes of angiotensin ii type 1 receptor. Reports of Morphology, 24(2), 14-21. https://doi.org/https://doi.org/10.31393/morphology-journal-2018-24(2)-02